세계의 듀센 근이영양증 시장 보고서(2025년)

Duchenne muscular dystrophy is a genetic condition causing progressive muscle loss, impacting skeletal, cardiac, and lung muscles. It results from a mutation in the gene responsible for dystrophin production, a crucial protein for healthy muscle function.

Duchenne Muscular Dystrophy therapies involve mutation suppression and the exon skipping approach. Exon skipping, a prevalent form of alternative splicing, removes introns and intervals on a pre-mRNA molecule, typically functioning as exons of a gene, when forming the final mRNA. Therapeutic classes include molecular-based therapies and steroid therapy, administered through oral, parenteral, and other routes. These therapies are distributed via hospital pharmacies, online pharmacies, and retail pharmacies, serving end-users such as hospitals, homecare, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The duchenne muscular dystrophy market research report is one of a series of new reports from The Business Research Company that provides Duchenne muscular dystrophy optical components market statistics, including Duchenne muscular dystrophy optical components industry global market size, regional shares, competitors with a Duchenne muscular dystrophy optical components market share, detailed Duchenne muscular dystrophy optical components market segments, market trends, and opportunities, and any further data you may need to thrive in the Duchenne muscular dystrophy optical components industry. This Duchenne muscular dystrophy optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The duchenne muscular dystrophy market size has grown strongly in recent years. It will grow from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to genetic understanding and diagnostic advances, clinical trial progress, patient advocacy and awareness, orphan drug designation and incentives, collaborative research initiatives.

The duchenne muscular dystrophy market size is expected to see strong growth in the next few years. It will grow to $1.72 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to emerging gene therapies, precision medicine approaches, expanded access to therapies, long-term follow-up studies, regulatory advancements. Major trends in the forecast period include integration of digital health technologies, technological advancements in therapeutics, gene therapies and genetic medicines, regulatory support for orphan drugs, precision medicine approaches.

The forecast of 8.2% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. patients by increasing costs of genetic testing kits and mobility aids imported from the UK and the Netherlands, potentially reducing treatment accessibility and raising long-term care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of chronic diseases is expected to fuel the growth of the Duchenne muscular dystrophy market in the coming years. Chronic diseases, defined as health conditions with symptoms lasting a year or more, include Duchenne muscular dystrophy, which emphasizes the importance of targeted therapies to address the unique needs of individuals with this genetic disorder. This focus underlines the broader role of personalized medicine in managing and potentially reducing the impact of chronic conditions. For example, in January 2023, the National Library of Medicine, a U.S.-based government agency, projected that the number of Americans aged 50 and older with at least one chronic condition will increase to 142.66 million by 2050. Consequently, the rising prevalence of chronic diseases is anticipated to drive the Duchenne muscular dystrophy market forward.

The increasing demand for personalized medicine is expected to drive the growth of the Duchenne muscular dystrophy (DMD) market in the coming years. Personalized medicine customizes medical treatments based on an individual's unique genetic, environmental, and lifestyle factors, enhancing therapeutic precision and effectiveness. In the context of DMD, personalized medicine tailors treatments to specific patient needs, improving efficacy and overall health outcomes. For instance, in February 2023, the Personalized Medicine Coalition, a U.S.-based membership organization, reported that 12 new personalized medicines were approved in 2022, representing about 34% of all new therapies-a marked increase from previous years. This trend in personalized medicine is fueling growth in the DMD market by advancing tailored approaches to managing this genetic disorder.

Leading companies in the Duchenne muscular dystrophy (DMD) market are advancing technological solutions, such as enhanced clinical trial design, to streamline drug development, improve patient outcomes, and expedite the regulatory approval of new therapies. Clinical trial design involves systematically organizing trials to assess treatment safety and efficacy, including setting objectives, choosing participants, and determining analysis methods. For example, in March 2024, the Critical Path Institute (C-Path), a U.S.-based nonprofit, launched the DMD Clinical Trial Simulator (CTS). Developed by C-Path's Duchenne Regulatory Science Consortium, this tool enhances the planning of DMD efficacy studies by offering features like performance modeling, scenario simulations, and trial efficiency improvements. Accessible through C-Path's website and the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), the CTS aids researchers and pharmaceutical companies in optimizing clinical trials for DMD therapies, supporting the growth of innovation in the market.

Major players in the Duchenne muscular dystrophy market are directing their efforts towards product innovations, notably the development of the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). This innovative therapy involves introducing functional copies of the dystrophin gene into affected individuals, aiming to correct the genetic mutation responsible for the progressive muscle degeneration associated with DMD. For instance, in June 2023, Sarepta Therapeutics, a US-based biopharmaceutical company specializing in RNA-based treatments for rare and infectious diseases, announced the FDA approval of ELEVIDYS, marking a significant milestone as the first gene therapy for Duchenne Muscular Dystrophy. This pioneering one-time treatment employs advanced gene therapy technology to target the root cause of the disease genetically. The approval of ELEVIDYS represents a paradigm shift in DMD treatment, moving beyond traditional supportive care approaches. It holds the potential to enhance patients' quality of life and life expectancy, showcasing the transformative impact of gene therapy on addressing rare diseases.

In December 2022, Solid Biosciences, a US-based life sciences company dedicated to advancing a portfolio of neuromuscular and cardiac programs, acquired AavantiBio for an undisclosed amount. This strategic acquisition positions the combined company to concentrate on the development of a diverse range of neuromuscular and cardiac programs, with a focus on advancing SGT-003, Solid's next-generation gene transfer candidate designed for the treatment of Duchenne muscular dystrophy. AavantiBio, Inc., a US-based biotechnology company, specializes in developing gene therapies aimed at transforming the lives of patients with rare genetic diseases.

Major companies operating in the duchenne muscular dystrophy market include Pfizer Inc., GlaxoSmithKline plc, PerkinElmer Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., WAVE Life Sciences Ltd., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc.

North America was the largest region in the Duchenne muscular dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the duchenne muscular dystrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The duchenne muscular dystrophy market includes revenues earned by entities by providing respiratory therapy, physical therapy and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Duchenne Muscular Dystrophy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on duchenne muscular dystrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for duchenne muscular dystrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The duchenne muscular dystrophy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy: Mutation Suppression; Exon Skipping Approach
• 2) By Therapeutic Class: Molecular Based Therapies; Steroid Therapy
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Mutation Suppression: Antisense Oligonucleotides (ASOs); Small Molecules; Gene Therapy
• 2) By Exon Skipping Approach: Exon-Skipping Therapies; Combination Therapies; Clinical Trials And Investigational Drugs
• Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; PerkinElmer Inc.; BioMarin Pharmaceutical Inc.; Sarepta Therapeutics Inc.; PTC Therapeutics Inc.; Asklepios BioPharmaceutical Inc.; Catabasis Pharmaceuticals Inc.; Wave Life Sciences Ltd.; Bristol Myers Squibb Company; BridgeBio Pharma Inc.; Rocket Pharmaceuticals Inc.; Italfarmaco SpA; Solid Biosciences Inc.; Avidity Biosciences Inc.; Fulcrum Therapeutics Inc.; Akashi Therapeutics Inc.; WAVE Life Sciences Ltd.; Capricor Therapeutics Inc.; Santhera Pharmaceuticals Holding; Armagen Technologies Inc.; Dyne Therapeutics Inc.; Benitec Biopharma Limited; Edgewise Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Duchenne Muscular Dystrophy Market Characteristics

3. Duchenne Muscular Dystrophy Market Trends And Strategies

4. Duchenne Muscular Dystrophy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Duchenne Muscular Dystrophy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Duchenne Muscular Dystrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Duchenne Muscular Dystrophy Market Growth Rate Analysis
• 5.4. Global Duchenne Muscular Dystrophy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Duchenne Muscular Dystrophy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Duchenne Muscular Dystrophy Total Addressable Market (TAM)

6. Duchenne Muscular Dystrophy Market Segmentation

• 6.1. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mutation Suppression
• Exon Skipping Approach
• 6.2. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Molecular Based Therapies
• Steroid Therapy
• 6.3. Global Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Duchenne Muscular Dystrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.6. Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Mutation Suppression, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antisense Oligonucleotides (ASOs)
• Small Molecules
• Gene Therapy
• 6.7. Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Exon Skipping Approach, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exon-Skipping Therapies
• Combination Therapies
• Clinical Trials And Investigational Drugs

7. Duchenne Muscular Dystrophy Market Regional And Country Analysis

• 7.1. Global Duchenne Muscular Dystrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Duchenne Muscular Dystrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Duchenne Muscular Dystrophy Market

• 8.1. Asia-Pacific Duchenne Muscular Dystrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Duchenne Muscular Dystrophy Market

• 9.1. China Duchenne Muscular Dystrophy Market Overview
• 9.2. China Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Duchenne Muscular Dystrophy Market

• 10.1. India Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Duchenne Muscular Dystrophy Market

• 11.1. Japan Duchenne Muscular Dystrophy Market Overview
• 11.2. Japan Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Duchenne Muscular Dystrophy Market

• 12.1. Australia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Duchenne Muscular Dystrophy Market

• 13.1. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Duchenne Muscular Dystrophy Market

• 14.1. South Korea Duchenne Muscular Dystrophy Market Overview
• 14.2. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Duchenne Muscular Dystrophy Market

• 15.1. Western Europe Duchenne Muscular Dystrophy Market Overview
• 15.2. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Duchenne Muscular Dystrophy Market

• 16.1. UK Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Duchenne Muscular Dystrophy Market

• 17.1. Germany Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Duchenne Muscular Dystrophy Market

• 18.1. France Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Duchenne Muscular Dystrophy Market

• 19.1. Italy Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Duchenne Muscular Dystrophy Market

• 20.1. Spain Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Duchenne Muscular Dystrophy Market

• 21.1. Eastern Europe Duchenne Muscular Dystrophy Market Overview
• 21.2. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Duchenne Muscular Dystrophy Market

• 22.1. Russia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Duchenne Muscular Dystrophy Market

• 23.1. North America Duchenne Muscular Dystrophy Market Overview
• 23.2. North America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Duchenne Muscular Dystrophy Market

• 24.1. USA Duchenne Muscular Dystrophy Market Overview
• 24.2. USA Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Duchenne Muscular Dystrophy Market

• 25.1. Canada Duchenne Muscular Dystrophy Market Overview
• 25.2. Canada Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Duchenne Muscular Dystrophy Market

• 26.1. South America Duchenne Muscular Dystrophy Market Overview
• 26.2. South America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Duchenne Muscular Dystrophy Market

• 27.1. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Duchenne Muscular Dystrophy Market

• 28.1. Middle East Duchenne Muscular Dystrophy Market Overview
• 28.2. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Duchenne Muscular Dystrophy Market

• 29.1. Africa Duchenne Muscular Dystrophy Market Overview
• 29.2. Africa Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Duchenne Muscular Dystrophy Market Competitive Landscape And Company Profiles

• 30.1. Duchenne Muscular Dystrophy Market Competitive Landscape
• 30.2. Duchenne Muscular Dystrophy Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. PerkinElmer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Duchenne Muscular Dystrophy Market Other Major And Innovative Companies

• 31.1. PTC Therapeutics Inc.
• 31.2. Asklepios BioPharmaceutical Inc.
• 31.3. Catabasis Pharmaceuticals Inc.
• 31.4. Wave Life Sciences Ltd.
• 31.5. Bristol Myers Squibb Company
• 31.6. BridgeBio Pharma Inc.
• 31.7. Rocket Pharmaceuticals Inc.
• 31.8. Italfarmaco SpA
• 31.9. Solid Biosciences Inc.
• 31.10. Avidity Biosciences Inc.
• 31.11. Fulcrum Therapeutics Inc.
• 31.12. Akashi Therapeutics Inc.
• 31.13. WAVE Life Sciences Ltd.
• 31.14. Capricor Therapeutics Inc.
• 31.15. Santhera Pharmaceuticals Holding

32. Global Duchenne Muscular Dystrophy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy Market

34. Recent Developments In The Duchenne Muscular Dystrophy Market

35. Duchenne Muscular Dystrophy Market High Potential Countries, Segments and Strategies

• 35.1 Duchenne Muscular Dystrophy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Duchenne Muscular Dystrophy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Duchenne Muscular Dystrophy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer